
Ayala Pharmaceuticals, Inc. – NASDAQ:AYLA
Ayala Pharmaceuticals stock price monthly change
Ayala Pharmaceuticals stock price quarterly change
Ayala Pharmaceuticals stock price yearly change
Ayala Pharmaceuticals key metrics
Market Cap | N/A |
Enterprise value | N/A |
P/E | -0.27 |
EV/Sales | -4.31 |
EV/EBITDA | 0.08 |
Price/Sales | 14.08 |
Price/Book | 1.01 |
PEG ratio | N/A |
EPS | -2.48 |
Revenue | 692K |
EBITDA | -37.42M |
Income | -38.01M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -5182.28% |
Oper. margin | -5059.97% |
Gross margin | -179.9% |
EBIT margin | -5059.97% |
EBITDA margin | -5408.82% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAyala Pharmaceuticals stock price history
Ayala Pharmaceuticals stock forecast
Ayala Pharmaceuticals financial statements
Mar 2022 | 458K | -10.02M | -2189.3% |
---|---|---|---|
Jun 2022 | 38K | -8.21M | -21605.26% |
Sep 2022 | 91K | -10.18M | -11195.6% |
Dec 2022 | 105K | -9.58M | -9131.43% |
2022-05-16 | -0.68 | -0.66 |
---|---|---|
2022-08-15 | -0.65 | -0.54 |
2022-11-04 | -0.49 | -0.66 |
Mar 2022 | 30647000 | 5.82M | 19.02% |
---|---|---|---|
Jun 2022 | 1270000 | 6.66M | 524.49% |
Sep 2022 | 14260000 | 6.10M | 42.78% |
Dec 2022 | 4581000 | 5.68M | 123.99% |
Mar 2022 | -9.98M | 0 | 44K |
---|---|---|---|
Jun 2022 | -7.02M | 0 | 44K |
Sep 2022 | -9.33M | 0 | 468K |
Dec 2022 | -8.16M | -2K | -615K |
Ayala Pharmaceuticals alternative data
Aug 2023 | 35 |
---|---|
Sep 2023 | 35 |
Oct 2023 | 35 |
Nov 2023 | 35 |
Dec 2023 | 35 |
Jan 2024 | 35 |
Feb 2024 | 35 |
Mar 2024 | 35 |
Apr 2024 | 35 |
May 2024 | 35 |
Jun 2024 | 35 |
Jul 2024 | 35 |
Ayala Pharmaceuticals other data
Period | Buy | Sel |
---|---|---|
May 2020 | 1575225 | 0 |
Jul 2020 | 5 | 0 |
Aug 2020 | 5 | 0 |
Sep 2020 | 11 | 0 |
Dec 2020 | 4 | 0 |
Jan 2021 | 0 | 23872 |
Feb 2021 | 0 | 36126 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | GORDON GARY B. officer: Chief Me.. | Common Stock | 3,000 | $5.16 | $15,480 | ||
Option | GORDON GARY B. officer: Chief Me.. | Stock Option | 3,000 | $5.16 | $15,480 | ||
Sale | GORDON GARY B. officer: Chief Me.. | Common Stock | 3,000 | $5.16 | $15,480 | ||
Sale | MAMLUK RONI director, officer.. | Common Stock | 10,800 | $17.4 | $187,920 | ||
Sale | MAMLUK RONI director, officer.. | Common Stock | 7,126 | N/A | N/A | ||
Sale | MAMLUK RONI director, officer.. | Common Stock | 15,200 | N/A | N/A | ||
Sale | MAMLUK RONI director, officer.. | Common Stock | 1,406 | N/A | N/A | ||
Option | GORDON GARY B. officer: Chief Me.. | Stock Option | 3,000 | N/A | N/A | ||
Sale | GORDON GARY B. officer: Chief Me.. | Common Stock | 3,000 | N/A | N/A | ||
Option | GORDON GARY B. officer: Chief Me.. | Common Stock | 3,000 | N/A | N/A |
Patent |
---|
Application Filling date: 14 May 2020 Issue date: 4 Aug 2022 |
Application COMPOSITIONS COMPRISING CD20 INHIBITORS AND BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THEREOF Filling date: 6 May 2019 Issue date: 9 Dec 2021 |
Application COMBINATION COMPOSITIONS COMPRISING BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THEREOF Filling date: 5 May 2019 Issue date: 12 Aug 2021 |
Application COMBINATION COMPOSITIONS COMPRISING BISFLUOROALKYL-1,4- BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THEREOF Filling date: 22 Oct 2020 Issue date: 11 Feb 2021 |
Application COMBINATION OF IMMUNOTHERAPEUTICS AND BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR TREATING LYMPHOMAS Filling date: 24 Sep 2019 Issue date: 19 Mar 2020 |
Application COMPOSITIONS COMPRISING BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR TREATING ADENOID CYSTIC CARCINOMA Filling date: 27 Sep 2019 Issue date: 23 Jan 2020 |
Insider | Compensation |
---|---|
Mr. Yossi Maimon CPA, M.B.A., CPA, MBA (1971) Chief Financial Officer, Sec. & Treasurer | $692,180 |
Dr. Roni Mamluk Ph.D. (1967) Pres, Chief Executive Officer & Director | $635,600 |
Dr. Gary B. Gordon M.D., Ph.D. (1953) Chief Medical Officer | $550,310 |
-
When is Ayala Pharmaceuticals's next earnings date?
Unfortunately, Ayala Pharmaceuticals's (AYLA) next earnings date is currently unknown.
-
Does Ayala Pharmaceuticals pay dividends?
No, Ayala Pharmaceuticals does not pay dividends.
-
What is Ayala Pharmaceuticals's stock symbol?
Ayala Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "AYLA".
-
What is Ayala Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Ayala Pharmaceuticals?
Shares of Ayala Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Ayala Pharmaceuticals's key executives?
Ayala Pharmaceuticals's management team includes the following people:
- Mr. Yossi Maimon CPA, M.B.A., CPA, MBA Chief Financial Officer, Sec. & Treasurer(age: 54, pay: $692,180)
- Dr. Roni Mamluk Ph.D. Pres, Chief Executive Officer & Director(age: 58, pay: $635,600)
- Dr. Gary B. Gordon M.D., Ph.D. Chief Medical Officer(age: 72, pay: $550,310)
-
How many employees does Ayala Pharmaceuticals have?
As Jul 2024, Ayala Pharmaceuticals employs 35 workers.
-
When Ayala Pharmaceuticals went public?
Ayala Pharmaceuticals, Inc. is publicly traded company for more then 5 years since IPO on 8 May 2020.
-
What is Ayala Pharmaceuticals's official website?
The official website for Ayala Pharmaceuticals is ayalapharma.com.
-
How can i contact Ayala Pharmaceuticals?
Ayala Pharmaceuticals can be reached via phone at 857 444 0553.
Ayala Pharmaceuticals company profile:

Ayala Pharmaceuticals, Inc.
ayalapharma.comNASDAQ
35
Biotechnology
Healthcare
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Rehovot, 7670104
CIK: 0001797336
ISIN: US05465V1089
CUSIP: 05465V108